Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models

Pharmacology Research and Perspectives

Volumn 3, Issue 3, 2015, Pages

  Jain, Mukul R ^a   Giri, Suresh R ^a   Trivedi, Chitrang ^a   Bhoi, Bibhuti ^a   Rath, Akshyaya ^a   Vanage, Geeta ^b   Vyas, Purvi ^a   Ranvir, Ramchandra ^a   Patel, Pankaj R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b NATIONAL INSTITUTE FOR RESEARCH IN REPRODUCTIVE HEALTH   (India)

Author keywords

Anti diabetic; dual PPAR agonist; glitazar; hypertriglyceridemia; insulin sensitizer; lipaglyn

Indexed keywords

ADIPONECTIN; ANTILIPEMIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SAROGLITAZAR; TRIACYLGLYCEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALLITRICHINAE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FAT TOLERANCE TEST; FEMALE; HAMSTER; HUMAN; HUMAN CELL; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; SPECTROPHOTOMETRY; ZUCKER RAT;

EID: 85021653258     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.136     Document Type: Article

References (43)

1. Agrawal RP, Sharma P, Pal M, Kochar A, Kochar DK (2006). Magnitude of dyslipedemia and its association with micro and macro vascular complications in type 2 diabetes: a hospital based study from Bikaner (Northwest India). Diabetes Res Clin Prac 73: 211–214.
2. Ammerschlaeger M, Beigel J, Klein KU, Mueller SO (2004). Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes. Toxicol Sci 78: 229–240.
3. Aronoff S, Rosenbalt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000). Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 23: 1605–1611.
4. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M (2007). PPAR dual agonists: are they opening Pandora's box? Pharmacological research. J Ital Pharmacol Soc 56: 91–98.
5. Balfour JB, Plosker GL (1999). Rosiglitazone. Drugs 57: 921–930.
6. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. (2012). Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97: 2969–2989.
7. Berlie HD, Kalus JS, Jaber LA (2007). Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 76: 279–289.
8. Boden G (1994). Mechanism of fatty acid induced inhibition of glucose uptake. J. Clin. Invest. 93: 2438–2446.
9. Boden G, Homko C, Mozzoli M, Zhang M, Kresge K, Cheung P (2007). Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes 56: 248–255.
10. Boullart ACI, Graaf JD, Stalenhoef AF (2012). Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta 1821: 867–875.
11. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, et al. (2004). Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53: 701–710.
12. Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, et al. (2003). Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140: 527–537.
13. Cziraky MJ (2004). Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc 44: 478–488.
14. Desvergene B, Wahli W (1999). Peroxisome proliferator activated receptors: nuclear control of metabolism. Endocrinol. Rev. 20: 649–688.
15. Fruchart JC, Duriez P (2006). Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42: 39–64.
16. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wangiverson P, et al. (1986). Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. J. Clin. Invest. 78: 1287–1295.
17. Goldberg IJ (1996). Lipoprotein lipase and lipolysis. J. Lipids Res. 37: 693–707.
18. Goldberg IJ (2001). Diabetic dyslipidemia: statins versus fibrates in the treatment of diabetic dyslipidemia. Program and abstracts of the 61st Scientific Sessions of the American Diabetes Association; June: 22–26.
19. Goodpaster BH, Kelly DE (1998). Role of muscle intriglyceride metabolism. Curr Opin Lipidol 9: 231–236.
20. Green S (1992). Nuclear receptors and chemical carcinogenesis. TIPS 13: 251–255.
21. Hermans MP, Ahn SA, Rousseau MF (2010). log(TG)/HDL-C is related to both residual cardiometabolic risk and b-cell function loss in type 2 diabetes males. Cardiovasc Diabetol 9: 88–97.
22. Heuvel JPV (1999). Peroxisome proliferator activated recepetor (PPAR) and carcinogenesis. Toxicol Sci 47: 1–8.
23. Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, et al. (2014). A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther 16: 63–71.
24. Kiess W, Bottner A, Bluher S, Raile K, Galler A, Kapellen TM (2004). Type 2 diabetes mellitus in children and adolescents the beginning of a renal catastrophe? Nephrol Dial Transplant 19: 2693–2696.
25. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, SakamotoN Nambu S, et al. (1988). Improvement of glucose tolerance in NIDDM by clofibrate. Randomised double-blind study. Diabe Care 11: 495–499.
26. Kumar V, Madhu SV, Singh G, Gambhir JK (2010). Post-prandial hypertriglyceridemia in patients with type 2 diabetes mellitus with and without macrovascular disease. J Assoc Physicians India 58: 603–607.
27. Minnich A, Tian N, Byan L, Bilder G (2001). A potent PPARα agonist stimulates mitochondrial fatty acid b-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 280: E270–E279.
28. Misra A, Luthra K, Vikram NK (2004). Dyslipidemia in Asian Indians: determinants and significance. J Assoc Physicians India 52: 137–142.
29. Muačević-Katanec D, Reiner Z (2011). Diabetic dyslipidemia or ‘diabetes lipidus’? Expert Rev Cardiovasc Ther 9(3): 341–348.
30. Nicholls SJ, Tuzcu M, Wolski K, Bayturan O, Lavoie A, Uno K (2011). Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients. J Am Coll Cardiol 57: 153–159.
31. Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471.
32. Ogawa S, Takeuchi K, Sugimura K, Fukuda M, Lee R, Ito S, et al. (2000). Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism 49: 331–334.
33. Pai V, Paneerselvam A, Mukhopadhyay S, Bhansali A, Kamath D, Shankar V, et al. (2014). A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol 8(1): 132–141.
34. Patel C, Wyne KL, McGuire DK (2005). Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2: 61–66.
35. Quarfordt SH, Michalopoulos G, Schirmer B (1982). The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem 257: 14642–14647.
36. Rader DJ (2007). Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 120(3): S12–S18.
37. Randle PJ, Garland PB, Hales CN, Newholme EA (1963). The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789.
38. Rubenstrunk A, Hanf R, Hum DW, FruchartJC Staels B (2007). Safety issues and prospects for future generations of PPAR modulators. Biochimicaet Biophysica Acta 1771: 1065–1081.
39. Samadfam R, Awori M, Bénardeau A, Bauss F, Sebokova E, Wright M (2012). Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats. J Endocrinol 212(2): 179–186.
40. Seber S, Ucak S, Ukcan B, Altuntas Y (2006). The effect of dual PPAR α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clin Pract 71: 52–58.
41. Taskinen MR (2002). Diabetic dyslipidemia. Atheroscler Suppl 3: 47–51.
42. Valabhji J, Watson M, Cox J, Poulter C, Elwig C, Elkeles RS (2003). Type 2 diabetes presenting as diabetic ketoacidosis in adolescence. Diabet Med 20: 416–417.
43. Wild S, Roglic G, Green A, Sicree R, King H (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–1053.